In recent years sclerosing encapsulating peritonitis (SEP) has been recognized as a serious complication of continuous ambulatory peritoneal dialysis (CAPD). First described by Denis et al. in 1980 (1) , it is rare in North America and Australia (2, 3) . In Europe over 40 cases were reported in the past year. Mean patient age was 45 years and mortality rate was 80%. Clinical features included wasting, loss of peritoneal transport function, reduced ultrafiltration, and bowel obstruction (4) (5) (6) (7) .
Pathophysiologically, SEP is an inflammatory process that transforms the peritoneal membrane into a thick fibrous tissue surrounding and compressing bowel loops. Postmortem studies reveal obliteration of the peritoneal cavity by fibrous adhesions, loculation with protein fluid, and extreme thickening of the peritoneal membrane sometimes associated with ileus (8) .
The etiology remains uncertain. No single cause was identified in a CAPD registry evaluation of 34 of 59 reported cases (2), but five factors predominated: (1) recurrent bacterial infection, (2) lengted of time exposure to peritoneal dialysis, (3) use of antiseptic agents, (4) acetate as dialysate base, and (5) prescription of beta blocking drugs.
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Recurrent Bacterial Peritonitis
As SEP has been associated with repeated episodes of peritonitis, the inflammatory process may be the initiating factor -by increasing the protein of the effluent and inducing destruction of the mesothelial layer. The type of organism involved may also play a role, the coagulase positive staphylococcus being a more frequent cause of adhesions. Various bacteria release endotoxin, which then stimulates monocytes to produce interleukin-1. This in turn causes fibroblasts to proliferate and deposit collagen. There may also be differences in host resistance, some patients being known to develop a predominately eosinophilic peritonitis with peripheral eosinophilia, possibly induced by non-infectious contaminants (9) . Patients who have a lower percentage of eosinophils in the early months of CAPD are more likely to develop peritonitis, and their peritoneal eosinophil count is usually near zero at the time of peritonitis. Thus a higher peritoneal count suggests either a more competent immune system or possibly a direct protective effect of eosinophils against early peritonitis. The severity and the duration of the inflammation may also be an important factor, by increasing protein exudation and destroying the mesothelium. If peritoneal dialysis is stopped too soon after a severe peritonitis, the collection of an exudative ascites could set the stage for neomembranes to form, surround, and compress the intestinal loops.
Time Spent on Dialysis
The longer a patient stays on CAPD the more episodes of peritonitis he will develop, as well as being exposed to chemicals or particulate contaminants in peritoneal dialysis fluids (10) . Time in itself has not been clearly shown to be an independent risk factor.
Antiseptics
Iodinated antiseptics such as povidone are used frequently, and traces may enter the system at connecting sites. Chlorhexidine, popular mainly in Eu-rope, has been strongly associated with peritoneal reaction and with the development of SEP (11), the trouble being caused either by the chlorhexidine itself or by the alcoholic solvent used in a spray to disinfect the connecting site.
Sodium hypochloride, when used to fill the limb of a Y connector system (12) (13) (14) , may also be washed into the abdominal cavity in trace amounts after connection. Accidental introduction of a bolus of disinfectant solution into the abdomen has been reported on 11 occasions (2).
It resulted in sudden abdominal pain, probably a peritoneal reaction, which disappeared after 2-3 rapid exchanges.
Another suspect is formaldehyde, used in the reverse osmosis water treatment and implicated as a possible factor in four patients with SEP (13, 15 ). Yet so far the strongest case has been made for chlorhexidine (16) .
Acetate as Dialysate Base
In Europe, where SEP is more frequent, the peritoneal dialysate often contains acetate rather than lactate.
Not all SEP patients have been dialyzed with acetate (17, 18). Yet this agent could predispose to SEP in some cases because of its vasodilating action. Acetate also has a lower ph, which sometimes actually causes abdominal pain on infusion, and is also known to lower the ultrafiltration rate of the peritoneal membrane, though this seems to be associated with a more rapid absorption of glucose rather than due to a thickening of the membrane (19, 20) .
Beta Blocking Drugs
Beta blocking agents such as propranolol, metoprolol, and atenolol have been occasionally associated with sclerosing peritonitis in patients never treated by CAPD (21) . In a European survey on SEP, 55% of patients had received beta blocking agents (2), suggesting that these agents could play a role in some cases.
394

Bacterial Filters
Bacterial filters in the inflowing dialysate, used to reduce the incidence of peritonitis, have been suspected to be associated with SEP. Shaldon et al. showed that bacteria retained in the filter produced endotoxin which penetrate the filter. They suggested that endotoxin causes monocytes to produce interleukin-1, which then stimulates fibroblasts and leads to collagen formation (14) . Yet not all patients with SEP have been exposed to such filters.
Peritoneal Catheter
As several types of catheters are being used, they may attract cellular elements or fibrin in different degrees. Migration of the catheter may also produce local irritation, as conceivably could the mobilization of plasticizers and particulate matter from the peritoneal catheter, the tubing, or the dialysate bag.
Treatment and Prevention of SEP
Once SEP has fully developed the fibrosis increases even after peritoneal dialysis is discontinued. In severe peritonitis it may be wise to continue with exchange in an effort to reduce the likelihood of severe fibrosis rather than to discontinue peritoneal dialysis. A change of the peritoneal catheter may be necessary if antibiotic therapy is not successful in overcoming the peritonitis. At the present there is no known treatment for SEP. Therefore all efforts have to be directed at prevention. As indicated in this review, no single factor can explain all cases of SEP. In a French survey there were three patients who had no previous peritonitis before they developed SEP, thus showing that peritoneal infection may not be a prerequisite for SEP development. These patients, however, received acetate containing dialysate almost exclusively (93%), whereas ten of their patients, with the highest peritonitis incidence, were never dialyzed on acetate (2) .
To summarize our review, we would conclude that the incidence of SEP could be markedly reduced if the exposure of the peritoneal cavity to bacteria, endotoxin, acetate, and chemical disinfectants could be reduced or eliminated. More work needs to be done to further delineate these potential risk factors, and hopefully eradicate this devastating complication. 
